The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
A randomised controlled trial with prolonged‐release oral oxycodone and naloxone to prevent and reverse opioid‐induced constipation
Abstract
Background:Opioid‐induced constipation can have a major negative impact on patients’ quality of life. This randomised, double‐blinded study evaluated the analgesic efficacy of prolonged‐release (PR) oral oxycodone when co‐administered with PR oral naloxone, and its impact on opioid‐induced constipation in patients with severe chronic pain. Another objective was to identify the optimal dose ratio of oxycodone and naloxone. Methods:A total of 202 patients with chronic pain (mainly non‐cancer related, 2.5% of patients had cancer‐related pain) under stable oral oxycodone therapy (40, 60 or 80mg/day) were randomised to receive 10, 20, 40mg/day naloxone or placebo. After a 4‐week maintenance phase, patients received oxycodone only for 2 weeks. Pain intensity was evaluated using a numerical analogue scale and bowel function was assessed using the bowel function index. Results:No loss of analgesic efficacy with naloxone was observed. Mean pain intensity scores on randomisation were comparable for placebo, 10mg, 20mg and 40mg naloxone dose, and remained unchanged during treatment. Bowel function improved with increasing naloxone dose. Naloxone 20mg and 40mg significantly improved bowel function at the end of the maintenance phase compared with placebo (p<0.05). Overall, the combination was well tolerated, with no unexpected adverse events. There was a trend towards an increased incidence of diarrhoea with higher doses of naloxone. The 2:1 oxycodone/naloxone ratio was identified as the most suitable for further development. Conclusion:Co‐administration of PR oral naloxone and PR oral oxycodone is associated with a significant improvement in bowel function compared with PR oral oxycodone alone, with no reduction in the analgesic efficacy of oxycodone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of oxycodone in neuronathic pain: A randomized trial in postherpetic neuralgia
N. Watson, C. P., & Babul, N. (1998) · Neurology · doi:10.1212/wnl.50.6.1837 · Cited by 646
Strategies to Manage the Adverse Effects of Oral Morphine: An Evidence-Based Report
Cherny, N., Ripamonti, C., Pereira, J., Davis, C., Fallon, M., McQuay, H., Mercadante, S., Pasternak, G., Ventafridda, V., & for the Expert Working Group of the European Association of Palliative Care Network (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2542 · Cited by 626
Opioid-Induced Bowel Dysfunction: Pathophysiology and Potential New Therapies
Kurz, A., & Sessler, D. I. (2003) · Drugs · doi:10.2165/00003495-200363070-00003 · Cited by 587
Incidence, Prevalence, and Management of Opioid Bowel Dysfunction
Pappagallo, M. (2001) · The American Journal of Surgery · doi:10.1016/s0002-9610(01)00782-6 · Cited by 531
Watson, P. C. N., Moulin, D., Watt-Watson, J., Gordon, A., & Eisenhoffer, J. (2003) · Pain · doi:10.1016/s0304-3959(03)00160-x · Cited by 510
Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial
Gimbel, J. S., Richards, P., & Portenoy, R. K. (2003) · Neurology · doi:10.1212/01.wnl.0000057720.36503.2c · Cited by 469
Insights into opioid action in the intestinal tract
De Luca, A., & Coupar, I. M. (1996) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)02053-5 · Cited by 286
Management of common opioid-induced adverse effects.
Swegle, J., & Logemann, C. D. (2006) · PubMed · Cited by 277
Opioids and the gut: pharmacology and current clinical experience
De Schepper, H. U., Cremonini, F., Park, M. ‐., & Camilleri, M. (2004) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2004.00513.x · Cited by 214
Treatment of opioid-induced constipation with oral naloxone: A pilot study
Culpepper-Morgan, J. A., Inturrisi, C. E., Portenoy, R. K., Foley, K., Houde, R. W., Marsh, F., & Kreek, M. J. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.106 · Cited by 208
Oral naloxone reverses opioid-associated constipation
Meissner, W., Schmidt, U., Hartmann, M., Kath, R., & Reinhart, K. (2000) · Pain · doi:10.1016/s0304-3959(99)00185-2 · Cited by 204
Self-citationLow-Dose Oral Naloxone Reverses Opioid-Induced Constipation and Analgesia
Liu, M., & Wittbrodt, E. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(01)00369-4 · Cited by 204
Sykes, N. (1996) · Palliative Medicine · doi:10.1177/026921639601000208 · Cited by 197
Oxycodone: a review of its use in the management of pain
Riley, J., Eisenberg, E., Müller-Schwefe, G., Drewes, A., & Arendt-nielsen, L. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253708 · Cited by 162
Peptide opioid antagonist separates peripheral and central opioid antitransit effects.
Shook, J. E., Pelton, J. T., Hruby, V. J., & Burks, T. F. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11008-2 · Cited by 145
NALOXONE, A SPECIFIC OPIOID ANTAGONIST, REVERSES CHRONIC IDIOPATHIC CONSTIPATION
Kreek, M.-J., Hahn, E. F., Schaefer, R., & Fishman, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91684-7 · Cited by 133
Treatment of opioid-induced gut dysfunction
Holzer, P. D. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.181 · Cited by 113
Management of opioid-induced constipation
Thorpe, D. M. (2001) · Current Pain and Headache Reports · doi:10.1007/s11916-001-0037-7 · Cited by 70
Management of opioid-induced bowel dysfunction in cancer patients
Tamayo, A. C., & Diaz-Zuluaga, P. (2004) · Supportive Care in Cancer · doi:10.1007/s00520-004-0649-7 · Cited by 60
Metabolites of Naloxone in Human Urine
Weinstein, S. H., Pfeffer, M., Schor, J. M., Indindoli, L., & Mintz, M. (1971) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600601030 · Cited by 55
Cited by
Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines
Fallon, M., Giusti, R., Aielli, F., Hoskin, P., Rolke, R., Sharma, M., & Ripamonti, C. I. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy152 · Cited by 954
Opioid receptors in the gastrointestinal tract
Holzer, P. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.03.012 · Cited by 377
Diagnosis and treatment of chronic constipation - a European perspective
Tack, J., Müller-Lissner, S., Stanghellini, V., Boeckxstaens, G., Kamm, M. A., Simren, M., Galmiche, J.-P., & Fried, M. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01709.x · Cited by 304
Larkin, P. J., Cherny, N. I., La Carpia, D., Guglielmo, M., Ostgathe, C., Scotté, F., & Ripamonti, C. I. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy148 · Cited by 273
Opioid-Induced Constipation: Challenges and Therapeutic Opportunities
Camilleri, M. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.30 · Cited by 262
Metadata
- Authors
- Meissner, W., Leyendecker, P., Mueller‐Lissner, S., Nadstawek, J., Hopp, M., Ruckes, C., Wirz, S., Fleischer, W., & Reimer, K.
- Venue
- European Journal of Pain
- Publisher
- Wiley
- Published
- 2009-01
- Volume
- 13
- Issue
- 1
- Pages
- 56-64
- ISSN
- 1090-3801 (ISSN-L)
- 1532-2149
- OpenAlex
- W2163255559
- Cited by
- 257
- References
- 20
- FWCI
- 27.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.